半夏糖浆联合头孢泊肟酯治疗小儿急性支气管炎的临床研究  

Clinical study of Banxia Syrup combined with cefpodoxime proxetil in treatment of children with acute bronchitis

作　　者：李淑娟[1] 梁宏[1] 陈晓轶 董利利[1] LI Shu-juan;LIANG Hong;CHEN Xiao-yi;DONG Li-li(Children's Hospital affiliated to Zhengzhou University,Henan Children’s Hospital Zhengzhou Children’s Hospital,Zhengzhou 450018,China)

机构地区：[1]郑州大学附属儿童医院,河南省儿童医院,郑州儿童医院,河南郑州450018

出　　处：《现代药物与临床》2021年第12期2552-2555,共4页Drugs & Clinic

基　　金：河南省医学科技攻关计划联合共建项目(2018020614)。

摘　　要：目的探讨半夏糖浆联合头孢泊肟酯治疗小儿急性支气管炎的临床疗效。方法回顾性分析2019年3月—2021年3月在郑州大学附属儿童医院进行治疗的108例急性支气管炎患儿,根据用药差别分为对照组和治疗组,每组各54例。对照组口服头孢泊肟酯干混悬剂,每次5 mg/kg,每12 h 1次,每日最大剂量不超过0.2 g;治疗组在对照组基础上口服半夏糖浆,3岁以下、5 mL/次,3~6岁、10 mL/次,6岁以上、15 mL/次,3次/d。两组均治疗10 d进行效果比较。观察两组的临床疗效,比较两组症状改善时间、相关评分和血清学指标。结果经治疗,治疗组的总有效率是98.15%,显著高于对照组的85.19%(P<0.05)。经治疗,治疗组发热、咳嗽、咳痰和肺部啰音临床症状改善时间明显短于对照组(P<0.05)。经治疗,两组咳嗽VAS、CARIFS评分均较治疗前显著降低,但LCQ评分均显著提高(P<0.05);且治疗后治疗组相关评分改善优于对照组(P<0.05)。经治疗,两组血清超敏C反应蛋白(hs-CRP)、可溶性髓系细胞触发受体-1(sTREM-1)、降钙素原(PCT)、半胱氨酰白三烯(CysLTs)、白细胞介素13(IL-13)水平均显著降低(P<0.05);且治疗后,治疗组炎症介质水平显著低于对照组(P<0.05)。结论半夏糖浆联合头孢泊肟酯治疗急性支气管炎患儿具有较好的临床疗效,不仅可以改善患儿症状,还可促进机体促炎因子水平下降,有利于提高患儿生活质量,有着良好临床应用价值。Objective To investigate the clinical efficacy of Banxia Syrup combined with cefpodoxime proxetil in treatment of children with acute bronchitis. Methods A retrospective analysis was performed on 108 children with acute bronchitis treated in Children’s Hospital affiliated to Zhengzhou University from March 2019 to March 2021, and they were divided into control group and treatment group according to medication difference, with 54 cases in each group. Patients in the control group were po administered with Cefpodoxime Proxetil for Suspension, 5 mg/(kg·time), once every 12 h, and the maximum daily dose should not exceed 0.2 g. Patients in the treatment group were po administered with Banxia Syrup on the basis of the control group, under 3 years old, 5 mL/time, 3 to 6 years old, 10 mL/time, over 6 years old, 15 mL/time, 3 times daily. The two groups were treated for 10 days. The clinical efficacy of the two groups was observed, and the improvement time, correlation score and serological indicators of the two groups were compared.Results After treatment, the total effective rate in treatment group was 98.15%, significantly higher than 85.19% in control group(P < 0.05). After treatment, the improvement time of fever, cough, expectoration and pulmonary rales in the treatment group was significantly shorter than that in the control group(P < 0.05). After treatment, cough VAS and CARIFS scores in two groups were significantly decreased compared with before treatment, but LCQ scores were significantly increased(P < 0.05). After treatment, the correlation score of the treatment group was better than that of the control group(P < 0.05). After treatment, serum hs-CRP, soluble myeloid triggering receptor-1(STREM-1), procalcitonin(PCT), cyste-leukotriene(CysLTs) and interleukin 13(IL-13) levels in two groups were significantly decreased(P < 0.05). After treatment, the level of inflammatory mediators in treatment group was significantly lower than that in control group(P < 0.05). Conclusion Banxia Syrup combined with cefpodox

关 键 词：半夏糖浆 头孢泊肟酯干混悬剂 急性支气管炎 临床症状改善时间 超敏C反应蛋白 

分 类 号：R974[医药卫生—药品] R985[医药卫生—药学]